Current Trends in Dietary Supplement Toxicity: Epidemiological Data and Statistical Risk Analyses

Mishra, S., Stierman, B., Gahche, J. J., & Potischman, N. (2021). Dietary supplement use among adults: United States, 2017-2018. NCHS Data Brief, (399), 1-8. PMID: 33663653.

Stierman, B., Couch, C. A., Gahche, J. J., & Mishra, S. (2026). Dietary supplement use: United States, August 2021-August 2023. NCHS Data Brief, (561), 1-11. https://doi.org/10.15620/cdc/252445.

Tucker, J., Fischer, T., Upjohn, L., Mazzera, D., & Kumar, M. (2018). Unapproved pharmaceutical ingredients included in dietary supplements associated with US Food and Drug Administration warnings. JAMA Network Open, 1(6), e183337. https://doi.org/10.1001/jamanetworkopen.2018.3337.

Farquhar, H. (2026). Disproportionality analysis of dietary supplement adverse events in the FDA CAERS database, 2004-2025. Food and Chemical Toxicology, 215, 116225. https://doi.org/10.1016/j.fct.2026.116225.

U.S. Food and Drug Administration (FDA). (2026a). FDA 101: Dietary Supplements. Consumer Updates. Erişim tarihi: 28 Temmuz 2026.

National Institutes of Health, Office of Dietary Supplements (NIH ODS). (2026). Dietary Supplement Fact Sheets and Health Information. Erişim tarihi: 28 Temmuz 2026.

Navarro, V. J., Khan, I., Björnsson, E., Seeff, L. B., Serrano, J., & Hoofnagle, J. H. (2017). Liver injury from herbal and dietary supplements. Hepatology, 65(1), 363-373. https://doi.org/10.1002/hep.28813.

T.C. Tarım ve Orman Bakanlığı, Gıda ve Kontrol Genel Müdürlüğü. (2026a). Takviye Edici Gıdalar Kısıtlı Maddeler Listesi, 03.07.2026 tarihli sürüm. Erişim tarihi: 28 Temmuz 2026.

T.C. Tarım ve Orman Bakanlığı. (2026b). Gıda Güvenliği Bilgi Sistemi (GGBS): Onaylı Takviye Edici Gıdalar Listesi. Erişim tarihi: 28 Temmuz 2026.

Ronis, M. J. J., Pedersen, K. B., & Watt, J. (2018). Adverse effects of nutraceuticals and dietary supplements. Annual Review of Pharmacology and Toxicology, 58, 583-601. https://doi.org/10.1146/annurev-pharmtox-010617-052844.

U.S. Food and Drug Administration (FDA). (2026b). Mixing medications and dietary supplements can endanger your health. Consumer Updates. Erişim tarihi: 28 Temmuz 2026. https://www.fda.gov/consumers/consumer-updates/mixing-medications-and-dietary-supplements-can-endanger-your-health.

Hazell, L., & Shakir, S. A. W. (2006). Under-reporting of adverse drug reactions: A systematic review. Drug Safety, 29(5), 385-396. https://doi.org/10.2165/00002018-200629050-00003.

Bate, A., & Evans, S. J. W. (2009). Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiology and Drug Safety, 18(6), 427-436. https://doi.org/10.1002/pds.1742.

Beuhler, M. C., Feldman, R., Gummin, D. D., Mowry, J. B., Rivers, L. J., Brown, K., Pham, N. P. T., Johnson-O'Leary, K., Spyker, D. A., & Bronstein, A. C. (2025). 2024 Annual report of the National Poison Data System (NPDS) from America's Poison Centers: 42nd annual report. Clinical Toxicology. Advance online publication. https://doi.org/10.1080/15563650.2025.2571299.

Geller, A. I., Shehab, N., Weidle, N. J., Lovegrove, M. C., Wolpert, B. J., Timbo, B. B., Mozersky, R. P., & Budnitz, D. S. (2015). Emergency department visits for adverse events related to dietary supplements. New England Journal of Medicine, 373(16), 1531-1540. https://doi.org/10.1056/NEJMsa1504267.

Gudushauri, N., Navarro, V. J., & Halegoua-De Marzio, D. (2024). A comprehensive update in herbal and dietary supplement-induced liver injury. Clinical Liver Disease, 23(1), e0185. https://doi.org/10.1097/CLD.0000000000000185.

Likhitsup, A., Chen, V. L., & Fontana, R. J. (2024). Estimated exposure to 6 potentially hepatotoxic botanicals in US adults. JAMA Network Open, 7(8), e2425822. https://doi.org/10.1001/jamanetworkopen.2024.25822.

U.S. Food and Drug Administration (FDA). (2025). VITALITY may be harmful due to hidden drug ingredients. Safety notification, 10 February 2025.

U.S. Food and Drug Administration (FDA). (2026c). PRE-FORMANCE BLACK may be harmful due to hidden ingredient. Safety notification, 24 June 2026.

U.S. Food and Drug Administration (FDA). (2026d). FDA issues warning about certain supplements substituted with toxic yellow oleander. Safety alert, updated 11 March 2026.

Cohen, P. A. (2018). The FDA and adulterated supplements—dereliction of duty. JAMA Network Open, 1(6), e183329. https://doi.org/10.1001/jamanetworkopen.2018.3329.

U.S. Food and Drug Administration (FDA). (2026e). Human Foods Complaint System (HFCS). Human Foods Program. / How to report a problem with dietary supplements. Erişim tarihi: 28 Temmuz 2026.

Timbo, B. B., Chirtel, S. J., Ihrie, J., Oladipo, T., Velez-Suarez, L., Brewer, V., & Mozersky, R. (2018). Dietary supplement adverse event report data from the FDA Center for Food Safety and Applied Nutrition Adverse Event Reporting System (CAERS), 2004-2013. Annals of Pharmacotherapy, 52(5), 431-438. https://doi.org/10.1177/1060028017744316.

Lash, T. L., VanderWeele, T. J., Haneuse, S., & Rothman, K. J. (2021). Modern epidemiology (4th ed.). Wolters Kluwer.

Harrell, F. E., Jr. (2015). Regression modeling strategies: With applications to linear models, logistic and ordinal regression, and survival analysis (2nd ed.). Springer. https://doi.org/10.1007/978-3-319-19425-7.

Knol, M. J., & VanderWeele, T. J. (2012). Recommendations for presenting analyses of effect modification and interaction. International Journal of Epidemiology, 41(2), 514-520. https://doi.org/10.1093/ije/dyr218.

Evans, S. J. W., Waller, P. C., & Davis, S. (2001). Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiology and Drug Safety, 10(6), 483-486. https://doi.org/10.1002/pds.677.

Montastruc, J. L., Sommet, A., Bagheri, H., & Lapeyre-Mestre, M. (2011). Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database. British Journal of Clinical Pharmacology, 72(6), 905-908. https://doi.org/10.1111/j.1365-2125.2011.04037.x.

DuMouchel, W. (1999). Bayesian data mining in large frequency tables, with an application to the FDA Spontaneous Reporting System. The American Statistician, 53(3), 177-190. https://doi.org/10.1080/00031305.1999.10474456.

Benjamini, Y., & Hochberg, Y. (1995). Controlling the false discovery rate: A practical and powerful approach to multiple testing. Journal of the Royal Statistical Society: Series B (Methodological), 57(1), 289-300. https://doi.org/10.1111/j.2517-6161.1995.tb02031.x.

Van Calster, B., McLernon, D. J., van Smeden, M., Wynants, L., Steyerberg, E. W., & Topic Group 'Evaluating diagnostic tests and prediction models' of the STRATOS initiative. (2019). Calibration: The Achilles heel of predictive analytics. BMC Medicine, 17, 230. https://doi.org/10.1186/s12916-019-1466-7.

Qato, D. M., Wilder, J., Schumm, L. P., Gillet, V., & Alexander, G. C. (2016). Changes in prescription and over-the-counter medication and dietary supplement use among older adults in the United States, 2005 vs 2011. JAMA Internal Medicine, 176(4), 473-482. https://doi.org/10.1001/jamainternmed.2015.8581.

Hoofnagle, J. H., Bonkovsky, H. L., Phillips, E. J., Li, Y. J., Ahmad, J., Barnhart, H., Durazo, F., Fontana, R. J., Gu, J., Khan, I., Kleiner, D. E., Koh, C., Rockey, D. C., Seeff, L. B., Serrano, J., Stolz, A., Tillmann, H. L., Vuppalanchi, R., Navarro, V. J., & Drug-Induced Liver Injury Network. (2021). HLA-B*35:01 and green tea-induced liver injury. Hepatology, 73(6), 2484-2493. https://doi.org/10.1002/hep.31538.

Dwyer, J. T., Coates, P. M., & Smith, M. J. (2018). Dietary supplements: Regulatory challenges and research resources. Nutrients, 10(1), 41. https://doi.org/10.3390/nu10010041.

Harpaz, R., DuMouchel, W., Shah, N. H., Madigan, D., Ryan, P., & Friedman, C. (2012). Novel data-mining methodologies for adverse drug event discovery and analysis. Clinical Pharmacology & Therapeutics, 91(6), 1010-1021. https://doi.org/10.1038/clpt.2012.50.